

## PRESS INFORMATION

### **POWERSEAL™ Sealer/Divider: Olympus Fully Launches Next-Level Surgical Bipolar Energy Device in EMEA**

*POWERSEAL Family of Devices Strengthens Olympus' Energy Portfolio, Offers Surgeons Improved Performance and Ergonomics*

**Hamburg, May 25, 2023 – Olympus today announced the full market launch of POWERSEAL™ Sealer/Divider for the Europe, Middle East and Africa (EMEA) region. This multifunctional advanced bipolar device supports surgeons across multiple different medical specialties with state-of-the-art sealing, dissection, and grasping capabilities for both laparoscopic and open surgical treatments. It complements the existing unique hybrid technology of THUNDERBEAT and with this, strengthens Olympus' advanced energy portfolio.**

“We are thrilled to finally offer POWERSEAL to customers in the EMEA region after it's already proven its premium quality in many non-European markets around the world”, says Tilman Kamlah, Head of Surgical Endoscopy at Olympus Europa. “POWERSEAL supports treatments of major types of cancer, but also non-cancer conditions, offering reliable sealing of vessels, best-in-class dissection, and enhanced usability during surgery. With POWERSEAL, we are completing our comprehensive advanced energy portfolio allowing hospital departments to standardize, reduce costs and complexity.”

“Initial clinical experience has shown that the new 5mm POWERSEAL devices offer uniform tissue compression for consistently strong sealing,” said Justin A. Maykel, MD, Chief of Colon and Rectal Surgery at UMass Memorial Health. “The product design makes the devices both intuitive and safe to use.”

“I found that POWERSEAL was faster than other options”, said Nikhilesh R. Sekhar, MD, FACS, FASMBS, Senior Faculty of Surgery at the Icahn School of Medicine at Mount Sinai. “POWERSEAL provides quick bloodless seals of the vessels.”

#### **Maximum control with enhanced usability**

POWERSEAL's unique proprietary jaw design ensures maximum control of bleeding and enhanced dissection capability. It enables surgeons to completely focus on patient and process owing to best-in-class control, efficiency, safety and performance, whereas patients benefit from an increasingly minimally invasive treatment. POWERSEAL Sealer/Divider

reduces the squeezing force required to close the jaw – without sacrificing sealing strength.<sup>1</sup> Along with improved ergonomics that ensure the device fits comfortably in the hand, surgeons benefit from comfort during surgery all while delivering a superior user experience.

## **Best-in-class performance across various medical specialties**

POWERSEAL Sealer/Divider supports the treatment of colon, stomach, lung, and other major types of cancer – but also non-cancer conditions – and can therefore be applied in various medical specialties, from lower to upper gastrointestinal surgery and gynecology, as well as in urology and other areas. To name a selection of procedures targeted for treatment by POWERSEAL Sealer/Divider:

- Colorectal resection (removal of part of the colon with cancer)
- Bariatric surgery (surgical weight-loss procedure in which the stomach size is reduced)
- Total laparoscopic hysterectomy (minimally invasive method of removing a diseased or dysfunctional uterus)
- Nephrectomy (removal of kidney to treat kidney cancer, for example)

POWERSEAL Sealer/Divider is commercially available in EMEA as of today. For more information, please visit [www.olympus-europa.com/medical](http://www.olympus-europa.com/medical)

## **About Olympus**

At Olympus, we are committed to Our Purpose of making people's lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide best-in-class solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states.

For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world.

For more information, visit [www.olympus-europa.com](http://www.olympus-europa.com) and follow our LinkedIn account: [www.linkedin.com/company/OlympusMedEmea](https://www.linkedin.com/company/OlympusMedEmea)

---

<sup>1</sup> Internal test report – DN0046457.



**For questions or additional information, please contact:**

Matthias Gengenbach

Olympus Europa SE & Co. KG

+49 15142369420

[matthias.gengenbach@olympus.com](mailto:matthias.gengenbach@olympus.com)